Author | William M. Mendenhall, MD

Articles

Proton Therapy for Prostate Cancer

June 15, 2011

This review discusses the rationale, history, and current status of proton therapy for prostate cancer-and controversies regarding it.

Modulation of Dose Intensity in Aerodigestive Tract Cancers: Strategies to Reduce Toxicity

December 01, 2001

Dr. Rich and colleagues present a compelling argument for the manipulation of temporal and spatial treatment parameters in chemoradiation programs. In essence, the authors address the shielding of normal tissues from the effects of cytotoxic agents. With respect to radiotherapy, this can be achieved via physical shielding by computer-generated dose algorithms using elaborate new planning technology (eg, intensity-modulated radiation therapy [IMRT]), chemical shielding with radioprotectants (eg, amifostine [Ethyol]), or temporal shielding by altered-fractionation schemes that exploit the differential alpha/beta ratios between tumor and normal tissue (eg, hyperfractionation).

The Role of Amifostine as a Radioprotector

October 01, 2001

Effective radiotherapy for patients with cancer should include maximal tumor cell killing with minimal injury to normal tissue. Radiation doses that can be delivered, without causing severe damage to surrounding normal

Infusional Chemoradiation for Operable Rectal Cancer: Post-, Pre-, or Nonoperative Management?

March 01, 1997

Dr. Rich presents a comprehensive overview of adjuvant therapy for advanced operable rectal cancer. He emphasizes the roles of infusional chemoradiation in both the adjuvant setting and as sole therapy. Unless otherwise specified, the following comments pertain to clinically resectable B2-C (T3, N0-N1) adenocarcinoma of the rectum.